Doctor Byambasuren Ganbaatar
Institute of Health Biosciences- The University of Tokushima Graduate School, Tokushima (Japan)
Follow
Contributor content
Presentation
Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient
Presentation
Inhibition of S1P2 receptor ameliorates endothelial dysfunction and prevents atherogenesis in apolipoprotein-E-deficient Mice
Presentation
